Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of SHR-A2009 in Advanced Solid Tumors
jRCT2031220414Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of ruzaltatug rezetecan in Nonhematologic neoplasms and solid tumor, sponsored by Hengrui Therapeutics. Primary endpoints: Maximum tolerated dose (MTD) / maximum administered dose (MAD), Recommended Phase 2 dose (RP2D) and 1 more. Started Nov 2022; status: completed.
02
Drugs
ruzaltatug rezetecan
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2031220414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220414.